Neoadjuvant serplulimab combined with chemotherapy in locally advanced driver gene-negative squamous NSCLC: a multicenter observational study
BackgroundPrevious evidence demonstrated that neoadjuvant chemo-immunotherapy provides significant prognostic benefits for non-small cell lung cancer (NSCLC). While the efficacy of serplulimab, an anti-PD-1 monoclonal antibody, has been well establishe…